Eisai / Biogen recently reported positive top-line data for the 856-patient Phase II trial Study 201 for the anti-amyloid beta ("Abeta") protofibril mAb BAN2401 in early Alzheimer's disease ("AD"). This is the first time a late-stage trial in AD shows disease-modifying effects with regard to both Abeta reduction in the brain and an improvement of clinical function. Importantly, the data supports the Abeta hypothesis for AD therapy and is a much-needed development following a string of late-stage failures. This is good news for Probiodrug, whose lead asset PQ912 has a unique mechanism of action that inhibits the formation of toxic products of Abeta without interfering with important physiological processes. We understand that Probiodrug is exploring multiple options to finance the PQ912 Phase IIb trial that is expected to start enrolling patients in Q4/2018E. We maintain our OUTPERFORM recommendation.
13 Jul 2018
Positive read-across from BAN2401 Phase II data
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Positive read-across from BAN2401 Phase II data
Vivoryon Therapeutics N.V. (0R3M:LON) | 0 0 0.4% | Mkt Cap: 102.2m
- Published:
13 Jul 2018 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Eisai / Biogen recently reported positive top-line data for the 856-patient Phase II trial Study 201 for the anti-amyloid beta ("Abeta") protofibril mAb BAN2401 in early Alzheimer's disease ("AD"). This is the first time a late-stage trial in AD shows disease-modifying effects with regard to both Abeta reduction in the brain and an improvement of clinical function. Importantly, the data supports the Abeta hypothesis for AD therapy and is a much-needed development following a string of late-stage failures. This is good news for Probiodrug, whose lead asset PQ912 has a unique mechanism of action that inhibits the formation of toxic products of Abeta without interfering with important physiological processes. We understand that Probiodrug is exploring multiple options to finance the PQ912 Phase IIb trial that is expected to start enrolling patients in Q4/2018E. We maintain our OUTPERFORM recommendation.